Signalisation PI3K/Akt/mTOR
Les inhibiteurs de la signalisation PI3K/Akt/mTOR sont des composés qui ciblent les voies de la phosphoinositide 3-kinase (PI3K), de la kinase Akt et de la cible de la rapamycine chez les mammifères (mTOR). Ces voies sont des régulateurs critiques de la croissance cellulaire, de la survie, du métabolisme et de l'autophagie, ce qui en fait des cibles clés dans la recherche sur le cancer et les troubles métaboliques. Inhiber ces voies peut aider à contrôler la croissance et la prolifération tumorales, offrant ainsi des stratégies thérapeutiques potentielles pour divers cancers et autres maladies caractérisées par une signalisation cellulaire dysrégulée. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de haute qualité de PI3K/Akt/mTOR pour soutenir vos recherches en oncologie, signalisation cellulaire et maladies métaboliques.
Sous-catégories appartenant à la catégorie "Signalisation PI3K/Akt/mTOR"
- AMPK(158 produits)
- ATM/ATR(71 produits)
- ADN-PK(51 produits)
- EGFR(572 produits)
- MELK(7 produits)
- PDK(9 produits)
- PI3K(242 produits)
- S6 Kinase(9 produits)
- gsk-3(112 produits)
- mTOR(144 produits)
Affichez 2 plus de sous-catégories
1038 produits trouvés pour "Signalisation PI3K/Akt/mTOR"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Epitinib succinate
CAS :<p>Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.</p>Formule :C28H32N6O6Degré de pureté :98.02% - 99.79%Couleur et forme :SolidMasse moléculaire :548.59JR-AB2-011
CAS :<p>JR-AB2-011: selective mTORC2 inhibitor, IC50 = 0.36μM, blocks Rictor-mTOR, Ki = 0.19μM, cytotoxic in glioblastoma.</p>Formule :C17H14Cl2FN3OSDegré de pureté :98.33% - 98.33%Couleur et forme :SolidMasse moléculaire :398.28Falnidamol
CAS :<p>Falnidamol (BIBX 1382), an oral selective EGFR inhibitor, IC50 3 nM, weak on ErbB2 and others, anti-cancer pyrimido-pyrimidine.</p>Formule :C18H19ClFN7Degré de pureté :98.816%Couleur et forme :SolidMasse moléculaire :387.84EGFR-IN-9
CAS :<p>EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M).</p>Formule :C29H24N4O3Degré de pureté :99.8%Couleur et forme :SolidMasse moléculaire :476.53Cloperastine fendizoate
CAS :<p>Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).</p>Formule :C40H38ClNO5Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :648.19GS-9901
CAS :<p>GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.</p>Formule :C22H17ClFN9ODegré de pureté :98.60% - 99.92%Couleur et forme :SolidMasse moléculaire :477.88EGFR-IN-99
CAS :<p>EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor for the study of non-small cell lung cancer (NSCLC).</p>Formule :C25H22FN7O3Degré de pureté :97.75%Couleur et forme :SolidMasse moléculaire :487.49A-935142
CAS :<p>A-935142 enhances hERG (Kv 11.1) channels, slows inactivation, promotes activation, and shortens repolarization.</p>Formule :C18H19F3N2O2Degré de pureté :98.97% - 99.91%Couleur et forme :SolidMasse moléculaire :352.35EMI1
CAS :<p>EMI1 targets mutated EGFR in drug-resistant NSCLC research.</p>Formule :C20H18N2O3Degré de pureté :99.96%Couleur et forme :SolidMasse moléculaire :334.37PD 174265
CAS :<p>PD 174265 is an effective, selective and reversible inhibitor of epidermal growth factor receptor (EGFR) with an IC50 of 0.45 nM.</p>Formule :C17H15BrN4ODegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :371.23GSK-3β inhibitor 11
CAS :<p>GSK-3β inhibitor 11 (compound 21) is a potent inhibitor of glycogen synthase kinase-3β (GSK-3β) with an inhibitory concentration (IC50) of 10.02 μM.</p>Formule :C20H15N3O4SDegré de pureté :97.33%Couleur et forme :SolidMasse moléculaire :393.42Tyrphostin A25
CAS :<p>Tyrphostin A25 (Tyrphostin AG 82) is a specific EGFR tyrosine kinase inhibitor and GPR35 agonist with an IC50 value of 0.94 μM for GPR35 and an EC50 value of 5.</p>Formule :C10H6N2O3Degré de pureté :98.76%Couleur et forme :Yellow Green Powder /Off-White SolidMasse moléculaire :202.17SKLB 1028
CAS :<p>SKLB 1028, an oral EGFR/FLT3/Abl inhibitor, excels in AML and CML with Abl mutations.</p>Formule :C24H29N9Degré de pureté :99.90% - >99.99%Couleur et forme :SolidMasse moléculaire :443.55CGP77675
CAS :<p>CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and</p>Formule :C26H29N5O2Degré de pureté :99.66%Couleur et forme :SolidMasse moléculaire :443.54BIP-135
CAS :<p>BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor.</p>Formule :C21H13BrN2O3Degré de pureté :99.93%Couleur et forme :SolidMasse moléculaire :421.24ARN25068
CAS :<p>ARN25068 inhibits GSK-3β, FYN, DYRK1A kinases; acts in sub-micromolar range; combats tau hyperphosphorylation.</p>Formule :C19H18N6SDegré de pureté :99.75%Couleur et forme :SolidMasse moléculaire :362.45LY 456236 hydrochloride
CAS :<p>LY 456236 hydrochloride (MPMQ hydrochloride) is an mGlu1 receptor antagonist with an ic50 value of 143 nM.</p>Formule :C16H16ClN3O2Degré de pureté :99.95%Couleur et forme :SolidMasse moléculaire :317.77GSK-3 Inhibitor XIII
CAS :<p>GSK-3 InhibitorXIII, an ATP-competitive GSK-3 inhibitor (Ki: 24 nM), can be used to study diabetes and obesity.</p>Formule :C18H15N5Degré de pureté :99.85% - 99.86%Couleur et forme :SolidMasse moléculaire :301.35Larotinib
CAS :<p>Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.</p>Formule :C24H26ClFN4O4Degré de pureté :98.45%Couleur et forme :SolidMasse moléculaire :488.94AZ044
CAS :<p>AZ044 is a potent, selective inhibitor of type III phosphatidylinositol-4-kinase alpha-subtype (PI4KIIIalpha).</p>Formule :C24H27N3O3SDegré de pureté :99.5%Couleur et forme :SolidMasse moléculaire :437.55YKL-06-062
CAS :<p>YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor that inhibits SIK1, SIK2 and SIK3 with IC50s of 2.12 nM, 1.40 nM and 2.86 nM.</p>Formule :C31H39N7ODegré de pureté :99.87%Couleur et forme :SolidMasse moléculaire :525.69PQR514
CAS :<p>PQR514: more potent pan-PI3K inhibitor than predecessor PQR309, exhibits strong anticancer activity in vitro and in OVCAR-3 model.</p>Formule :C16H20F2N8O2Degré de pureté :98.77% - 99.19%Couleur et forme :SolidMasse moléculaire :394.38MELK-8a hydrochloride
CAS :<p>MELK-8a hydrochloride is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK, IC50 = 2 nM). </p>Formule :C25H33ClN6ODegré de pureté :99.87%Couleur et forme :SolidMasse moléculaire :469.02PKI-166
CAS :<p>PKI-166: oral EGF-R tyrosine kinase inhibitor (IC50: 0.7 nM), halts growth & spread of many human cancers, including pancreatic.</p>Formule :C20H18N4ODegré de pureté :99.2%Couleur et forme :SolidMasse moléculaire :330.38RS1-PDK1 inhibitor
CAS :<p>RS1-PDK1 inhibitor (RS 1) is a selective inhibitor of the protein kinase PDK1 that can be used to treat and prevent disease or disorders.</p>Formule :C15H9ClN2O2S3Degré de pureté :98.12%Couleur et forme :SolidMasse moléculaire :380.89TGX-115
CAS :<p>TGX-115 inhibits PI 3-K p110β (IC50=0.13μM) & p110δ (IC50=0.63μM), treats various cardiovascular diseases.</p>Formule :C20H20N2O3Degré de pureté :99.48%Couleur et forme :SolidMasse moléculaire :336.38Rezivertinib
CAS :<p>Rezivertinib (BPI-7711) is an EGFR inhibitor with antitumor activity and can be used to study central nervous system diseases.</p>Formule :C27H30N6O3Degré de pureté :99.26% - 99.89%Couleur et forme :SolidMasse moléculaire :486.57NVP-BAG956
CAS :<p>NVP-BAG956 is an ATP-competitive PI3K inhibitor (IC50s: 34/56/112/444 nM for PI3Kδ/PI3Kα/PI3Kγ/PI3Kβ).</p>Formule :C28H21N5Degré de pureté :99.25% - 99.80%Couleur et forme :SolidMasse moléculaire :427.5(R)-(-)-Rolipram
CAS :<p>(R)-(-)-Rolipram ((-)-Rolipram) is an R-enantiomer of Rolipram which is a PDE4 inhibitor.</p>Formule :C16H21NO3Degré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :275.34PF-249
CAS :<p>PF-249 (PF-06685249) is a β1-selective AMPK with an EC50 of 12 nM for AMPK α1β1γ1 and can be used in studies about diabetic nephropathy.</p>Formule :C17H16ClN3O3Degré de pureté :97.01%Couleur et forme :SolidMasse moléculaire :345.78SRX3207
CAS :<p>SRX3207 is an inhibitor of Syk and PI3K and relieves tumor immunosuppression.</p>Formule :C29H29N7O3SDegré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :555.65GSK-3β inhibitor 2
CAS :<p>GSK-3β inhibitor 2 (5-Thiazolecarboxamide,2-[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]-4-methoxy-) is a BBB-crossing and selective inhibitor of GSK-3β (IC50</p>Formule :C14H14N4O3SDegré de pureté :99.08%Couleur et forme :SolidMasse moléculaire :318.35YLF-466D
CAS :<p>YLF-466D (C24) is a newly developed AMPK activator, which inhibits platelet aggregation.</p>Formule :C29H20ClNO3Degré de pureté :97.74%Couleur et forme :SolidMasse moléculaire :465.93Sunvozertinib
CAS :<p>Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.</p>Formule :C29H35ClFN7O3Degré de pureté :98.11% - 99.63%Couleur et forme :SolidMasse moléculaire :584.08ABC1183
CAS :<p>ABC1183, an oral diaminothiazole, inhibits GSK3α/β, CDK9, hinders cancer cell growth, induces G2/M arrest, and modulates phosphorylation.</p>Formule :C18H14N4OSDegré de pureté :98.92%Couleur et forme :SolidMasse moléculaire :334.39(Z)-RG-13022
CAS :<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formule :C16H14N2O2Couleur et forme :SolidMasse moléculaire :266.29PI3Kδ-IN-17
CAS :<p>PI3Kδ-IN-17 (Compound S5) is a potent PI3K δ inhibitor, exhibiting an IC50 value of 2.82 nM and demonstrates significant efficacy in suppressing the</p>Formule :C23H24F3N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :487.48MTI-31
CAS :<p>MTI-31 (LXI-15029) is a potent oral mTORC1/2 inhibitor with a Kd of 0.20 nM, >5,000-fold selectivity, and an IC50 of 39 nM.</p>Formule :C26H30N6O3Degré de pureté :99.97%Couleur et forme :SolidMasse moléculaire :474.55PI3K/mTOR Inhibitor-14
CAS :<p>PI3K/mTOR Inhibitor-14 (compound Y-2) serves as a dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 171.4 nM and 10.1 nM , respectively, and</p>Formule :C28H30N8O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :558.66PI3K/mTOR Inhibitor-7
CAS :<p>Potent PI3K/mTOR inhibitor, 4.7x stronger than gedatolisib; IC50: 1.4 μM (PI3K), 0.3 μM (mTOR); impacts PI3K/Akt/mTOR pathway; research in cancer.</p>Formule :C29H33N9O4Couleur et forme :SolidMasse moléculaire :571.63LAS191954
CAS :<p>LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).</p>Formule :C20H15N9ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :397.39MIPS-21335
CAS :<p>MIPS-21335 is a potent PI3KC2α inhibitor with an IC50 value of 7 nM and additionally exhibits inhibitory activity against PI3KC2β, p110α, p110β, and p110δ with</p>Formule :C24H21N7O5Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :487.47MP7
CAS :<p>MP7 (PDK1 inhibitor) is a inhibitor of phosphoinositide-dependent kinase-1 (PDK1).</p>Formule :C28H22F2N4O4Degré de pureté :99.84% - 99.89%Couleur et forme :SolidMasse moléculaire :516.5ZL-2201
CAS :<p>ZL-2201 is a potent inhibitor of DNA-PK, demonstrating an IC50 value of 1 nM.</p>Formule :C20H25N9O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :503.54EGFR-IN-1
CAS :<p>EGFR-IN-1: an oral, irreversible EGFR inhibitor targeting L858R/T790M mutations with high selectivity, showing potent antitumor effects.</p>Formule :C28H30N6O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :514.58MSC2360844
CAS :<p>MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).</p>Formule :C26H27FN4O5SDegré de pureté :99.54% - 99.9%Couleur et forme :SolidMasse moléculaire :526.58SAR-260301
CAS :<p>SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).</p>Formule :C19H22N4O3Degré de pureté :99.74%Couleur et forme :SolidMasse moléculaire :354.4EGFR-IN-33
CAS :<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97PIK-inhibitors
CAS :<p>PIK-inhibitors (MDK34597) is a pan PI3K inhibitors, an analog of PI-103.</p>Formule :C19H17N5O2Degré de pureté :96.98%Couleur et forme :SolidMasse moléculaire :347.37EGFR-IN-71
CAS :<p>EGFR-IN-71 is a potent inhibitor of epidermal growth factor receptor (EGFR) (IC50= 3.7 μM). EGFR-IN-71 has research value in chordoma.</p>Formule :C16H9ClIN3Couleur et forme :SolidMasse moléculaire :405.62PI5P4K-β-IN-1
CAS :<p>PI5P4K-β-IN-1 (compound vs1) is a potent PI5P4K-β inhibitor with an IC50 of 0.80 μM [1].</p>Formule :C23H17Cl2N3O2Couleur et forme :SolidMasse moléculaire :438.31BGB-102
CAS :<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>Formule :C22H25BrN4O2Degré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :457.36Tenalisib R Enantiomer
CAS :<p>Tenalisib R Enantiomer is an R enantiomer of Tenalisib .</p>Formule :C23H18FN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :415.42JND3229
CAS :<p>JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.</p>Formule :C33H41ClN8O2Degré de pureté :98.75%Couleur et forme :SolidMasse moléculaire :617.18mTOR inhibitor-11
CAS :<p>mTOR inhibitor-11 (Compound 9) is a brain-penetrant compound capable of inhibiting mTOR with an IC50 of 21 nM for pS6.</p>Formule :C21H26N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :394.47DNA-PK-IN-10
CAS :<p>DNA-PK-IN-10 is a DNA-PK inhibitor utilized in the research of breast cancer and non-small cell lung cancer [1].</p>Formule :C25H28N6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :444.53BRD5648
CAS :<p>BRD5648 ((R)-BRD0705) is an inactive (R)-enantiomer of BRD0705.</p>Formule :C20H23N3ODegré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :321.42GNE-490
CAS :<p>GNE-490 is an effective inhibitor of pan-PI3K with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.</p>Formule :C18H22N6O2SDegré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :386.47TCS 21311
CAS :<p>TCS 21311 (NIBR3049) selectively inhibits JAK3 (IC50: 8 nM) and PKCα/θ & GSK3β; >100x selective over JAK1, JAK2, TYK2.</p>Formule :C27H25F3N4O4Degré de pureté :99.39% - ≥98%Couleur et forme :SolidMasse moléculaire :526.51LDHA/PDKs-IN-1
CAS :<p>Compound 20e inhibits PDKs (IC50: 0.8 μM) & LDHA (IC50: 0.15 μM), halts A549 cell growth, lowers lactate, boosts oxygen use.</p>Formule :C19H21FN2O4Couleur et forme :SolidMasse moléculaire :360.38(Rac)-BRD0705
CAS :<p>(Rac)-BRD0705 is a less active racemate of BRD0705. BRD0705 is an effective and selective inhibitor of GSK3α.</p>Formule :C20H23N3ODegré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :321.42MS 154
CAS :<p>MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.</p>Formule :C46H54ClFN8O8Couleur et forme :SolidMasse moléculaire :901.42WYE-23
CAS :<p>WYE-23 is an inhibitor of mammalian target of rapamycin (mTOR).</p>Formule :C26H32N8O4Couleur et forme :SolidMasse moléculaire :520.58T-00127_HEV1
CAS :<p>T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta(PI4KIIIβ, IC50 = 60 nM).</p>Formule :C22H29N5O3Degré de pureté :99.89%Couleur et forme :SolidMasse moléculaire :411.5mTOR inhibitor 9d
CAS :<p>mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia,</p>Formule :C21H23N5O3SDegré de pureté :99.08%Couleur et forme :SoildMasse moléculaire :425.517β-Hydroxywortmannin
CAS :<p>17β-Hydroxywortmannin is an orally active phosphatidylinositol-3-kinase (PI-3-kinase) inhibitor, exhibiting an IC50 of 0.5 nM and notably suppresses osteoclast resorption at an IC50 of 10 nM. Additionally, it demonstrates antitumor activity.</p>Formule :C23H26O8Couleur et forme :SolidMasse moléculaire :430.45EGFR-IN-74
<p>EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.</p>Formule :C32H28BrF3N6O4SCouleur et forme :SolidMasse moléculaire :729.57mTOR inhibitor 9b
CAS :<p>mTOR inhibitor 9b is an enzyme inhibitor of protein kinase mTOR he phosphatidylinositol 3-kinase PIK3CA with IC50s of 0.76 nm and 1.262 µM, respectively.mTOR</p>Formule :C21H23N5O2SDegré de pureté :99.52%Couleur et forme :SoildMasse moléculaire :409.5Dezapelisib
CAS :<p>Dezapelisib, an oral delta PI3K inhibitor, blocks PIP3 production and PI3K/AKT pathway, hindering tumor cell growth and survival.</p>Formule :C20H16FN7OSCouleur et forme :SolidMasse moléculaire :421.45Labuxtinib
CAS :<p>Labutinib is a selective inhibitor of the c-kit tyrosine kinase [1].</p>Formule :C20H16FN5O2Degré de pureté :99.77%Couleur et forme :SolidMasse moléculaire :377.37SU-11752
CAS :<p>SU-11752 selectively inhibits DNA-PK by competing with ATP, enhances ionizing radiation sensitivity without affecting cell cycle or ATM activity.</p>Formule :C26H27N3O5SCouleur et forme :SolidMasse moléculaire :493.57PAT-505
CAS :<p>PAT-505 is an autologous epidermal growth factor inhibitor.</p>Formule :C23H18ClF2N3O2SDegré de pureté :98.84%Couleur et forme :SolidMasse moléculaire :473.92BMS-599626 Hydrochloride
CAS :<p>BMS-599626 HCl (AC480 HCl) is an oral inhibitor of HER1, HER2, HER4 kinases, potentially blocking tumor growth. IC50: 22/32/190 nM.</p>Formule :C27H28ClFN8O3Degré de pureté :99.98%Couleur et forme :SolidMasse moléculaire :567.01ZLN024
CAS :<p>ZLN024 is an activator of AMPK allosteric.</p>Formule :C13H13BrN2OSDegré de pureté :99.751%Couleur et forme :SolidMasse moléculaire :325.22PI3K/mTOR Inhibitor-1
CAS :<p>PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)</p>Formule :C18H22FN5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :407.46CAL-130 Racemate
CAS :<p>CAL-130 Racemate is the racemate of CAL-130. CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Formule :C23H22N8ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :426.47HKI-357
CAS :<p>HKI-357 irreversibly inhibits EGFR/ERBB2 (IC50: 34/33 nM), blocks EGFR Y1068 autophosphorylation, and AKT/MAPK phosphorylation.</p>Formule :C31H29ClFN5O3Degré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :574.05PF-06459988
CAS :<p>PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.</p>Formule :C19H22ClN7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :431.88mTOR inhibitor-3
CAS :<p>mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments.</p>Formule :C25H30N8O2Degré de pureté :99% - 99.64%Couleur et forme :SolidMasse moléculaire :474.56Zandelisib
CAS :<p>Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.</p>Formule :C31H38F2N8ODegré de pureté :99.88%Couleur et forme :SolidMasse moléculaire :576.68Alpelisib hydrochloride
CAS :<p>Alpelisib hydrochloride (BYL-719) is an oral, selective PI3Kα inhibitor with anticancer properties.</p>Formule :C19H23ClF3N5O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :477.93PI3Kδ-IN-1
CAS :<p>PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).</p>Formule :C22H20F3N7O2Degré de pureté :99.85%Couleur et forme :SolidMasse moléculaire :471.44EGFR-IN-29
CAS :<p>EGFR-IN-29 is a potent EGFR inhibitor.</p>Formule :C36H46BrN8O2PCouleur et forme :SolidMasse moléculaire :733.685-Iodo-indirubin-3'-monoxime
CAS :<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Formule :C16H10IN3O2Couleur et forme :SolidMasse moléculaire :403.17Ampkinone
CAS :<p>Ampkinone is an indirect AMPK activator.</p>Formule :C31H23NO6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :505.52BPIQ-I
CAS :<p>BPIQ-I (PD 159121), an ATP-competitive EGFR tyrosine kinase inhibitor, exhibits potent anti-proliferative activity.</p>Formule :C16H12BrN5Couleur et forme :SolidMasse moléculaire :354.2LDHA/PDKs-IN-2
CAS :<p>Compound 20k is a dual LDHA/PDKs inhibitor; IC50: 0.7/1.6 μM. It boosts O2 use, cuts lactate, and slows A549 cancer cell growth (EC50: 15.7 μM).</p>Formule :C17H20N2O5Couleur et forme :SolidMasse moléculaire :332.35PI3K/mTOR Inhibitor-6
CAS :<p>Potent, stable PI3K/mTOR Inhibitor-6 surpasses gedatolisib in gastric fluid; 10 μM hinders PI3K/Akt/mTOR pathway, aids cancer research.</p>Formule :C30H34N10O4Couleur et forme :SolidMasse moléculaire :598.66NVP-QAV-572
CAS :<p>NVP-QAV-572 is a inhibitor of PI3K(IC50 of 10 nM).</p>Formule :C17H19F2N7O3S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :471.5Lifirafenib
CAS :<p>Lifirafenib (Beigene-283) is a potent inhibitor of RAF family kinases and EGFR in biochemical assays with IC50 of 23, 29 and 495 nM for the recombinant</p>Formule :C25H17F3N4O3Degré de pureté :98% - 98.25%Couleur et forme :SolidMasse moléculaire :478.42SAR502250
CAS :<p>SAR502250: potent, selective GSK3 inhibitor, IC50=12nM, oral, brain-penetrant, potential for AD research, antidepressant-like properties.</p>Formule :C19H18FN5O2Couleur et forme :SolidMasse moléculaire :367.38HER2-IN-5
CAS :<p>HER2-IN-5 is an effective inhibitor of orally active HER-2.</p>Formule :C27H33N7O3Couleur et forme :SolidMasse moléculaire :503.6CC214-1
CAS :<p>CC214-1 is an mTOR inhibitor that inhibits protein translation, induces autophagy, and is an in vitro tool compound for exploring the biology of mTOR kinases.</p>Formule :C20H21N7O2Degré de pureté :97.16%Couleur et forme :SolidMasse moléculaire :391.43Antitrypanosomal agent 14
CAS :<p>Antitrypanosomal agent 14 (Compound 1), a potent T.</p>Formule :C14H23N3OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :281.42A 1070722
CAS :<p>A 1070722: potent GSK-3 inhibitor, Ki = 0.6 nM for both α/β isoforms, crosses BBB, potential brain GSK-3 PET radiotracer.</p>Formule :C17H13F3N4O2Degré de pureté :99.9%Couleur et forme :SolidMasse moléculaire :362.31PT-65
CAS :<p>PT-65, a potent and selective GSK3 degrader, demonstrates the highest degradation capacity for GSK3α (DC50 = 28.3 nM) and GSK3β (DC50 = 34.2 nM) in SH-SY5Y cells, making it applicable for Alzheimer's disease research [1].</p>Formule :C51H63N13O12SCouleur et forme :SolidMasse moléculaire :1082.19PI5P4Kα-IN-1
CAS :<p>PI5P4Kα-IN-1 (Compound 13) is a phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) inhibitor, displaying IC50 values of 2 μM for PI5P4Kα and 9.4 μM for PI5P4Kβ</p>Formule :C20H17N3O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :363.43PI3K/mTOR Inhibitor-5
CAS :<p>PI3K/mTOR Inhibitor-5 is a potent dual inhibitor of PI3K and mTOR, displaying IC50 values of 86.9 nM (for PI3K) and 14.6 nM (for mTOR), respectively.</p>Formule :C32H40N10O3Couleur et forme :SolidMasse moléculaire :612.73Nazartinib S-enantiomer
CAS :<p>Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.</p>Formule :C26H31ClN6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :495.02PI3Kγ inhibitor 2
CAS :<p>PI3Kγ inhibitor 2 is an orally bioavailable inhibitor of PI3Kγ(Ki of 4 nM).</p>Formule :C20H18F3N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :433.38BX-320
CAS :<p>BX-320, a PDK1 inhibitor (IC50=30nM), selectively blocks Akt/p70S6K1 phosphorylation, induces apoptosis, and inhibits cancer cell growth.</p>Formule :C23H31BrN8O3Couleur et forme :SolidMasse moléculaire :547.45BEBT-109
CAS :<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Formule :C27H32N8O3Degré de pureté :97.26%Couleur et forme :SolidMasse moléculaire :516.6EGFR-IN-30
CAS :<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Formule :C28H33BrN7O2PCouleur et forme :SolidMasse moléculaire :610.49EGFR-IN-61
CAS :<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Formule :C33H37ClN8O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :629.15EGFR-IN-85
CAS :<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Formule :C26H30N8O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :486.57JGK-068S
CAS :<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Formule :C22H23BrFN5O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :488.35PI3K/mTOR Inhibitor-12
CAS :<p>PI3K/mTOR Inhibitor-12: oral, potent, selective; IC50: PI3Kα 0.06 nM, mTOR 3.12 nM; strong antitumor; less liver toxicity.</p>Formule :C27H27F2N9O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :611.62Simotinib
CAS :<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Formule :C25H26ClFN4O4Degré de pureté :99.7%Couleur et forme :SolidMasse moléculaire :500.95EGFR/CSC-IN-1
CAS :<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Formule :C54H54Cl2FN7O7S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1067.082′-Thioadenosine
CAS :<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Formule :C10H13N5O3SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :283.31DZD1516
CAS :<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Formule :C28H27F2N7O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :547.56EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Formule :C34H39ClFN7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :632.17GSK-3β inhibitor 8
CAS :<p>GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine</p>Formule :C20H20ClN5OSDegré de pureté :98.46%Couleur et forme :SolidMasse moléculaire :413.92EGFR-IN-36
CAS :<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Formule :C26H25ClN6O2Couleur et forme :SolidMasse moléculaire :488.97EGFR-IN-32
CAS :<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Formule :C31H34N6O3Couleur et forme :SolidMasse moléculaire :538.64AMPK-α1β1γ1 activator 1
CAS :<p>AMPK-α1β1γ1 activator 1 (M1), an acyl glucuronide metabolite derived from an Indole-3-carboxylic Acid-based AMPK activator, selectively activates the β1</p>Formule :C25H24ClNO9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :517.91EGFR-IN-87
CAS :<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Formule :C28H33N7O2Degré de pureté :98.64%Couleur et forme :SolidMasse moléculaire :499.61EGFR-IN-1 hydrochloride
CAS :<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Formule :C28H31ClN6O4Degré de pureté :99.16%Couleur et forme :SolidMasse moléculaire :551.04BGB-8035
CAS :<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formule :C24H31N5O4Degré de pureté :96.74%Couleur et forme :SolidMasse moléculaire :453.53EGFR/ErbB-2 inhibitor-1
CAS :<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Formule :C23H15ClFN3OS2Degré de pureté :98.93%Couleur et forme :SolidMasse moléculaire :467.97Sevabertinib
CAS :<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Formule :C24H25ClN4O5Degré de pureté :99.81%Couleur et forme :SolidMasse moléculaire :484.93Rheb inhibitor NR1
CAS :<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Formule :C25H19BrCl2N2O3SDegré de pureté :99.72%Couleur et forme :SolidMasse moléculaire :578.3PI3K-IN-54
CAS :<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Formule :C20H24F2N8O3Degré de pureté :98.15%Couleur et forme :SolidMasse moléculaire :462.45GSK-F1
CAS :<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Formule :C27H18F5N5O4SDegré de pureté :97.03%Couleur et forme :SolidMasse moléculaire :603.52PF-04979064
CAS :<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Formule :C24H26N6O3Degré de pureté :98.20% - ≥98%Couleur et forme :SolidMasse moléculaire :446.5PKI-402
CAS :<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Formule :C29H34N10O3Degré de pureté :99.94%Couleur et forme :SolidMasse moléculaire :570.65GSK-3 inhibitor 1
CAS :<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Formule :C22H17ClFN5O2Degré de pureté :98.42%Couleur et forme :SolidMasse moléculaire :437.85EGFR-IN-8
CAS :<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formule :C32H23ClF3N7O4Degré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :662.02GDC-0349
CAS :<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Formule :C24H32N6O3Degré de pureté :96.00% - 98.17%Couleur et forme :SolidMasse moléculaire :452.55GLPG3312
CAS :<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Formule :C23H21F2N5O3Degré de pureté :98.53%Couleur et forme :SolidMasse moléculaire :453.44EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Formule :C14H11BrN4O2SCouleur et forme :SolidMasse moléculaire :379.23DNA-PK-IN-15
CAS :<p>DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.</p>Formule :C23H23N9OCouleur et forme :SolidMasse moléculaire :441.49HER2-IN-7
CAS :<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Formule :C28H26F3N7O3Couleur et forme :SolidMasse moléculaire :565.55EGFR-IN-160
CAS :<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Formule :C15H12N2O4Couleur et forme :SolidMasse moléculaire :284.27EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Couleur et forme :SolidEGFR-IN-147
CAS :<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Formule :C13H13N5OCouleur et forme :SolidMasse moléculaire :255.275EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Formule :C24H15FO3Couleur et forme :SolidMasse moléculaire :370.37EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Formule :C27H25N3O6SCouleur et forme :SolidMasse moléculaire :519.57LAS195319
CAS :<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Formule :C29H26N10O3SCouleur et forme :SolidMasse moléculaire :594.65EGFR-IN-23
CAS :<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Formule :C36H44BrN10O3PCouleur et forme :SolidMasse moléculaire :775.68iMDK quarterhydrate
<p>iMDK quarterhydrate, PI3K inhibitor, blocks MDK growth; suppresses NSCLC safely with MEK inhibitor.</p>Formule :C21H15FN2O3SCouleur et forme :SolidMasse moléculaire :380.91ES-072
CAS :<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Formule :C25H27F3N8O2Couleur et forme :SolidMasse moléculaire :528.53EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Formule :C31H30FN7OCouleur et forme :SolidMasse moléculaire :535.61Tesevatinib tosylate
CAS :<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Formule :C31H33Cl2FN4O5SCouleur et forme :SolidMasse moléculaire :663.59PI3Kδ-IN-23
CAS :<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Formule :C30H30N6O5Couleur et forme :SolidMasse moléculaire :554.596DNA-PK-IN-6
CAS :<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Formule :C19H21N7OCouleur et forme :SolidMasse moléculaire :363.42EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Formule :C26H28ClN3O4Couleur et forme :SolidMasse moléculaire :481.975-Bromo-3-indoxylacetate
CAS :<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Formule :C10H8BrNO2Couleur et forme :SolidMasse moléculaire :254.08HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Formule :C19H14BrF3N2OCouleur et forme :SolidMasse moléculaire :423.23DNA-PK-IN-8
CAS :<p>DNA-PK-IN-8: Potent, selective oral DNA-PK inhibitor, IC50 = 0.8 nM, boosts anti-cancer effects with Doxorubicin.</p>Formule :C19H22N8O2Couleur et forme :SolidMasse moléculaire :394.43Andamertinib
CAS :<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Formule :C31H36N8O3Couleur et forme :SolidMasse moléculaire :568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Formule :C12H14N4OS2Couleur et forme :SolidMasse moléculaire :294.4Tyrphostin 63
CAS :<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Formule :C10H8N2OCouleur et forme :SolidMasse moléculaire :172.183EGFR-IN-125
CAS :<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Formule :C30H26N8OCouleur et forme :SolidMasse moléculaire :514.58PI3K-IN-27
CAS :<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Formule :C30H26F2N6O2SCouleur et forme :SolidMasse moléculaire :572.63PI3Kβ-IN-1
CAS :<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Formule :C25H14F2N8Couleur et forme :SolidMasse moléculaire :464.43ETP-47037
CAS :<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Formule :C20H27N9O3SCouleur et forme :SolidMasse moléculaire :473.55GSK3-IN-9
CAS :<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Formule :C18H20N4OCouleur et forme :SolidMasse moléculaire :308.378EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Couleur et forme :SolidEGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Formule :C26H27ClN6O2Couleur et forme :SolidMasse moléculaire :490.98PI3K-IN-26
CAS :<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Formule :C21H18N6OSCouleur et forme :SolidMasse moléculaire :402.47EGFR-IN-133
CAS :<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Formule :C27H29F2N7O3Couleur et forme :SolidMasse moléculaire :537.56EGFR-IN-132
CAS :<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Formule :C27H31N7O3Couleur et forme :SolidMasse moléculaire :501.58EGFR-IN-139
CAS :<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Formule :C27H25ClN2O4Couleur et forme :SolidMasse moléculaire :476.951Tarloxotinib bromide
CAS :<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Formule :C24H24Br2ClN9O3Degré de pureté :99.52%Couleur et forme :SolidMasse moléculaire :681.77Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Formule :C14H20N4O2Couleur et forme :SolidMasse moléculaire :276.33EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Formule :C33H28N6O3SCouleur et forme :SolidMasse moléculaire :588.68PI3kδ inhibitor 1
CAS :<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Formule :C28H33FN6O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :504.60PI4KIIIbeta-IN-11
CAS :<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Formule :C33H39N7O3Couleur et forme :SolidMasse moléculaire :581.71SST0116CL1
CAS :<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Formule :C22H31ClN4O6Couleur et forme :SolidMasse moléculaire :482.96EGFR-IN-149
CAS :<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Formule :C16H15N3OSCouleur et forme :SolidMasse moléculaire :297.375NS-062
CAS :<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Formule :C28H30Cl2F2N6O4Couleur et forme :SolidMasse moléculaire :623.48PF-5177624
CAS :<p>PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.</p>Formule :C25H25FN8O2Couleur et forme :SolidMasse moléculaire :488.52GSK-3β inhibitor 25
CAS :<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Formule :C16H15NOSCouleur et forme :SolidMasse moléculaire :269.361EGFR-IN-159
CAS :<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formule :C21H23N3O5Couleur et forme :SolidMasse moléculaire :397.4244-FPBUA
CAS :<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Formule :C31H23FO7Couleur et forme :SolidMasse moléculaire :526.51DNA-PK-IN-2
CAS :<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Formule :C20H23N5O3Couleur et forme :SolidMasse moléculaire :381.43HER2-IN-8
CAS :<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Formule :C26H25F2N9O3Couleur et forme :SolidMasse moléculaire :549.53NSC381467
CAS :<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formule :C20H16O7Couleur et forme :SolidMasse moléculaire :368.34PD-M6
CAS :<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>Formule :C30H39N9O6Couleur et forme :SolidMasse moléculaire :621.69BPI-15086
CAS :<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Formule :C29H33ClN8O4Couleur et forme :SolidMasse moléculaire :593.08BML-265
CAS :<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Formule :C18H15N3O2Couleur et forme :SolidMasse moléculaire :305.331GSK3β-IN-2
CAS :<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Formule :C25H18N4OCouleur et forme :SolidMasse moléculaire :390.437PI3K-IN-37
CAS :<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Formule :C25H26N6O2Couleur et forme :SolidMasse moléculaire :442.51DNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Formule :C21H21N5O2Couleur et forme :SolidMasse moléculaire :375.42EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Couleur et forme :SolidEGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Formule :C30H35FN6O3Couleur et forme :SolidMasse moléculaire :546.64NU5455
CAS :<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Formule :C34H33N3O5SCouleur et forme :SolidMasse moléculaire :595.71EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Formule :C16H16N4O2SCouleur et forme :SolidMasse moléculaire :328.39D-69491 hydrochloride
CAS :<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Formule :C25H26Cl2FN7O3Couleur et forme :SolidMasse moléculaire :562.42GSK3β-IN-1
CAS :<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Formule :C17H13FN2O4SCouleur et forme :SolidMasse moléculaire :360.36GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Formule :C27H23BrN4O2SCouleur et forme :SolidMasse moléculaire :547.47EGFR-IN-35
CAS :<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Formule :C25H24ClN7O2Couleur et forme :SolidMasse moléculaire :489.96GSK-3β inhibitor 26
CAS :<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Formule :C15H11N3O3Couleur et forme :SolidMasse moléculaire :281.266Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Formule :C27H22BN3OCouleur et forme :SolidMasse moléculaire :415.29EGFR-IN-126
CAS :<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Formule :C28H28BrFN4O3Couleur et forme :SolidMasse moléculaire :567.45SIK2-IN-3
CAS :<p>SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.</p>Formule :C23H24N6O2Couleur et forme :SolidMasse moléculaire :416.48HER2-IN-21
CAS :<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formule :C20H18N4O3SCouleur et forme :SolidMasse moléculaire :394.447GSK-3β inhibitor 6
<p>GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM.</p>Formule :C20H17BrN4Couleur et forme :SolidMasse moléculaire :393.28GSK-3β inhibitor 20
CAS :<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formule :C22H21N5O2SCouleur et forme :SolidMasse moléculaire :419.50
